Veyong Pass the EU EDQM Audit Once Again

On April 22, good news came! Hebei Veyong Pharmaceutical Co., Ltd. once again successfully obtained the EU CEP certification for ivermectin API issued by the European Agency for the Quality of Medicines (EDQM).

Ivermectin API is one of the main products of Veyong Pharma. It is well received by customers at home and abroad due to its strong stability, high quality and green production process. In 2018, it successfully obtained the US FDA certification.

The ivermectin CEP certificate is the European Pharmacopoeia adaptability certificate, which is not only recognized by all EU member states, but also recognized by many countries that recognize the status of the European Pharmacopoeia. Obtaining the CEP certificate again is the recognition of Veyong Pharma’s products in the international market, the embodiment of Veyong’s market competitiveness, and a significant sign of achieving high-quality business development in overseas markets.